Investigational drug · Phase 2
EDG-15400
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Heart Failure With Preserved Ejection Fraction.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "EDG-15400"
First trial start
2026
Aug 25, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EDG-15400", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heart Failure With Preserved Ejection Fraction
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "EDG-15400" as an intervention, largest first.
- A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)Recruiting
Edgewise Therapeutics, Inc.Industry
NCT07795814 · 90 participants (planned) · Start Aug 25, 2026 · Primary completion Dec 2027
Drug: EDG-15400 25 mg; Placebo to match EDG-15400 25 mg or 50 mg and 1 more · For: Heart Failure With Preserved Ejection Fraction
Sites: Birmingham, Alabama; Little Rock, Arkansas; Beverly Hills, California · 28 sites in all
Edgewise Therapeutics, Inc.Industry
NCT07177066 · 84 participants · Start Aug 20, 2025 · Primary completion Apr 29, 2026
Drug: EDG-15400; Placebo · For: Healthy Adults
Sites: Tempe, Arizona
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Heart Failure With Preserved Ejection Fraction
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-1893Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · Obstructive Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy
- HS235Phase 22 trials
35Pharma Inc., a GSK company · Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- TX000045Phase 22 trials
Tectonic Therapeutic · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction, Hypertension, Pulmonary
- JK07Phase 21 trial
Salubris Biotherapeutics Inc · Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.